STADA Arzneimittel AG — M&A Activity 2005

Apr 11, 2005

News Details

Ad-hoc | 11 April 2005 14:32

STADA acquires Portuguese Generics supplier Ciclum

Ad hoc announcement §15 WpHG Acquisition STADA acquires Portuguese Generics supplier Ciclum Ad hoc announcement transmitted by DGAP. The issuer is solely responsible for the content of this announcement. —————————————————————————— STADA Arzneimittel AG concluded today, April 11, 2005, the agreement on the purchase of 100% of the shares in the Portuguese generics supplier Ciclum Farma, Unipessoal LDA, Amadora, from a Swiss financial investor. The purchase price will amount to approx. EUR 31 million. The agreement will take effect subject to the usual contract implementation provisions as well as approval of the anti-trust authorities. Ciclum currently ranks as number 6 in the Portuguese generics market and achieved sales of approx. EUR 7.3 million in 2004. Ciclum is a sales company without any production facilities of its own; it offers a comprehensive product portfolio of currently 18 INN generics (i.e. generics sold under the name of the active ingredient with the company name as a suffix). Ciclum has a nationwide sales presence with approx. 25 sales representatives who focus on doctors. In 2004, Ciclum achieved sales growth of approx. 3%. Due to the addition of approx. 15 products to the portfolio in 2005, significant growth is anticipated in the future. So far, STADA has not had its own sales presence in Portugal. The acquisition will enable the Group to leverage existing or targeted EU-wide product approvals for generics through its own sales structures in Portugal as well. Further information: STADA Arzneimittel AG / Corporate Communications / Stadastrasse 2-18 / 61118 Bad Vilbel, Germany / Phone: +49(0) 6101 603-113 / Fax: +49(0) 6101 603-506 / E-mail: communications@stada.de Or visit our website at http://www.stada.com ISIN: DE0007251803 (MDAX); (MDAX); DE0007251845; DE0001069540; DE0001069557 WKN: 725180; 725184; 106954; 106955 Listed: Amtlicher Markt in Düsseldorf und Frankfurt End of ad hoc announcement (c)DGAP 11.04.2005 111432 Apr 05